[1] |
LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei.
Research progress of virus-mediated gene therapy in type 2 diabetes mellitu
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
|
[2] |
MENG Shi, WANG Zhongqun.
Research progress on human immunodeficiency virus-associated pulmonary arterial hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1431-1440.
|
[3] |
PENG Jing, SONG Jing, LUAN Jiajie.
Mesenchymal Stem Cells: a new discovery in the treatment of novel coronavirus pneumonia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1073-1079.
|
[4] |
ZHENG Lichun, WANG Xiang, WANG Wenmei.
Management strategies and suggestions on stomatological clinical trials under the influence of epidemic
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 213-216.
|
[5] |
TAO Chengjing, LIU Shourong, CHENG Xiaoxian, HU Jiannv, BAI Xiuli, ZHANG Suying, ZHAO Chun, ZUO Zhongbao.
Effects of different postpartum withdrawal time of tenofovir on hepatitis B virus markers, virology and biochemical indexes
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1146-1152.
|
[6] |
MU Xin, ZHAO Ying, ZHANG Lan, CUI Yimin, ZHANG Yongxiang, DU Guanhua.
Drug clinical trial of COVID-19 in China: A brief analysis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 869-877.
|
[7] |
SHAN Hui, DU Yinxiao, BAI Hequn, CHEN Junxia, HE Xiaolin, WANG Qian, HU Zijian, LV Cheng, CHEN Xiaoping.
Progress in the development of baicalein and its clinical pharmacology study
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 701-708.
|
[8] |
ZHANG Lu, LIN Liangmo, LIU Keke, HUANG Yamin, HUANG Xingxing, YANG Yongyu, XIAO Jian.
Therapeutic drug monitoring and pharmacokinetics of new coronavirus pneumonia antiviral drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 566-575.
|
[9] |
HUANG Zhijun, YANG Guoping.
Clinical trials during post-COVID pandemic: An interim review
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 591-594.
|
[10] |
WANG Xiaomin, YANG Guoping, WANG Bing, ZHONG Yuqiong, WU Ying, LIU Xing.
Ethical issues in the prevention and control of Coronavirus Disease 2019
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 329-333.
|
[11] |
LIU Qi, XIA Shuai, JIANG Shibo.
Research and development of antiviral drugs against new coronavirus 2019-nCoV
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 241-245.
|
[12] |
LUO Yi, JIANG Zhiwei.
Statistical consideration in the design of COVID-19 clinical trials in emergency
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 121-125.
|
[13] |
LAN Qiaoshuai, XIA Shuai, ZHOU Jie, WANG Qian, LU Lu.
New use of old drugs in the treatment of SARS-CoV-2 infection
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 126-134.
|
[14] |
HU Ke.
New coronavirus pneumonia: Question and confusion
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 141-143.
|
[15] |
SHEN Yajing, LI Lanjuan.
Effects of Coxsackievirus B3 infection on the expression of diabetes-related LncRNA in islet cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1101-1106.
|